China Meheco Group shares jump after agreement to import Pfizer’s COVID treatment paxlovid

SHANGHAI (Reuters) – Shares of China Meheco Group surged after the Chinese drug seller signed an agreement with Pfizer Inc to import and distribute the U.S. drugmaker’s oral COVID-19 treatment Paxlovid in mainland China.

Meheco shares opened up 10% in Shanghai.

(Reporting by Shanghai newsroom; Editing by Jacqueline Wong)